Investigating the role of TMEM16A in airway diseases
Official title: TMEM16A in human airway disease
Funded at Washington University · NIH-11064038 · Data updated 2026-11-12
This study is looking at how two proteins, TMEM16A and CLCA1, affect lung health and conditions like asthma and cystic fibrosis, with the goal of finding new ways to help people breathe better by improving mucus function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $604,458 |
| NIH project number | 5R01HL170198-02 |
| Project ID | NIH-11064038 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with cystic fibrosis or other mucus-obstructive airway diseases.
✕Less likely to help
Patients without airway diseases or those who do not have a genetic predisposition to conditions affecting TMEM16A may not benefit from this research.
What this research studies
This research focuses on understanding how the TMEM16A chloride channel and its regulator, CLCA1, influence airway health and diseases such as asthma and cystic fibrosis. By studying these interactions in human models, particularly those with cystic fibrosis, the research aims to uncover how these proteins affect mucus properties and airway function. The project will utilize advanced techniques to explore the biophysical characteristics of TMEM16A and its potential as a therapeutic target for mucus-obstructive diseases.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve airway function and mucus clearance for patients with airway diseases.
How similar studies have gone: Previous research has shown promise in targeting chloride channels for airway diseases, indicating that this approach could yield significant insights and advancements.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Brett, Thomas John — Washington University
- Study coordinator: Brett, Thomas John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.